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Abstract:
Omega-3 (n-3) and omega-6 (n-6) fatty acids have been known to be essential for normal
growth and dermal functions since the 1930s, and multiple benefits of n-3 fatty acids have been
recognized over the last 20 years. α-linoleic acid (ALA), an omega-3 fatty acid, is of particular
interest because of its suspected role in up-regulating global fatty acid oxidation in adipocytes
and skeletal muscle cells. ALA is a substrate for β-oxidation in humans, and also can be
elongated to longer-chain polyunsaturated fatty acids (PUFAs) in the endoplasmic reticulum via
interactions with desaturase and elongase enzymes. Under long-chain PUFAs deficient
conditions, ALA would be converted, but under normal conditions the ALA is competitively
inhibited from interacting with ∆6-Desaturase enzyme. N-3 and n-6 fatty acids are metabolized
by the same desaturation/elongations pathway; therefore, there exists the potential for
competitive inhibition when there are sufficient intracellular concentrations of both families of
fatty acids. The logical question that arises is: what happens to the ALA not allowed to
participate in the desaturase/elongation pathway? Clearly, it is going to be metabolized, but what
mechanisms are involved in this process and are they ALA-specific? The hypothesis is that the
mechanisms are not ALA-specific; therefore, the metabolism of surplus ALA will affect the
metabolism of other fatty acids. To determine if surplus ALA regulates global fatty oxidation,
experiments were ran using the C2C12 cell line of mouse adipocytes. After cells were grown,
differentiated, and labeled with 3H-palmitate, 15 different treatments containing various
concentrations of ALA, arachidonic acid (ARA), eicosapentaenoic acid (EPA), and
docosahexenoic acid (DHA) were added in vitro. The treatments that contained all four n-3 fatty
acids mimicked in vivo conditions (25µM ARA, 25µM 3:2 EPA:DHA) . Initial experiments
show a 141%, 41%, 195%, and 97% increase in fat oxidation in response to progressive
increases in ALA from 0 to 10, 25, 50, and 100µM ALA, respectively. These data show that
ALA does affect the oxidation of other fatty acids, although, the subsequent experiment did not
replicate the initial’s results. Therefore, more experiments need to be run to address the lack of
fatty acid oxidation dose-responsiveness. If in fact the initial experiment’s observations hold
true, some hypothesized mechanisms that might cause up-regulated of fatty acid oxidation are
increased activity of Carnitine Palmitoyl Transferase I (CPT-I), the ligand-activated
transcriptional factors peroxisomal proliferator activated receptor-α (PPARα) and PPARδ, and
such downstream effects as increased mitochondrial biogenesis.
Introduction:
Obesity has become an obvious killer in not only America, but throughout the world. A
combination of work-related stress, sedentary lifestyle, and poor nutrition has created and
allowed the prevalence of obesity to more than double since 19801. Now, 65% of the world’s
population lives in countries where obesity-related deaths have overtaken non-obesity-related
deaths1. Luckily, obesity is a preventable condition, and as the prevalence of obesity continues to
grow throughout the world, there is increasing interest in a possible solution amongst the
scientific community.
Previous Research:
This project evaluates the effect of a specific omega-3 (n-3) polyunsaturated fatty acid
(PUFA), but a more general perspective on the history of n-3 PUFA research is necessary to
understand the reasoning which led to this study’s focus.

Numerous studies have used diet-induced and genetically obese mice to study the effects
of n-3 PUFA on mice, effects such as: weight loss, fat reduction, and protective benefits against
the accumulation of body fat2. The diets among certain studies varied. Usually, the mice were
categorized into two groups, two high-fat diets with the second group being supplemented with
fish oil or EPA/DHA, a high-fat supplemented diet and low-fat/control diets, or a multiple highfat diets supplemented with different absolute amounts of EPA/DHA or fish oil3.
Multiple studies have supported the claim that long chain n-3 PUFA have protective
effects regarding body fat accumulation. Hainault et al. found that, although body weight did not
change, Wistar rats that consumed a lard-fish oil diet (33% lard, 20% casein, 30% starch, 2%
corn oil, 15% fish oil) had 20% less inguinal adipose tissue and 30% retroperitoneal and
epididymal adipose tissue after the 20-day study4. Parrish et al. found through a high-fat (20%
triglycerides from fish oil or 20% from lard oil) diet study, his Wistar rats in the fish oil group
did not differ in body weight from the lard oil group, but Parrish saw a significant reduction in
peririenal and epididymal fat from the lard oil group2. Several more studies delved further into
the correlation between n-3 PUFA supplementation and fat reduction, specifically discovering a
dose-dependent relationship5 and suggestion that DHA is primarily responsible for encouraging
reduction of cellularity and attenuation of visceral fat accumulation6.
The accumulating evidence for the beneficial effects of long chain n-3 PUFA is exciting.
Though, for the sake of fair argument, one 2006 study did offer contradicting evidence. Todoric
et al. examined body weight, metabolic changes, and genes regulating the inflammatory response
in C57BL/KsJ-leprdb/leprdb diabetes mice on high-fat diets7. He found that those mice on a highfat diet (30% of energy) which were given a n-3 PUFA-rich supplement actually had significant
weight gain compared with the mice on a n-6 PUFA-rich diet7. Although body fat was not a
parameter measured in the Todoric et al. study, the findings do lend to the speculation that long
chain n-3 PUFA have different metabolic impacts on mice with diabetes3. Contrastingly, the
study also provides support for n-3 PUFA interference with white adipose tissue
proinflammatory response of mice on obese mice7.
α-linolenic acid:
α-linolenic acid (18:3n-3, ALA) is an essential n-3 PUFA in the human diet and is the
principal fatty acid in the western diet8. ALA is converted to longer-chain PUFA in the
endoplasmic reticulum of the liver10 of human adults, and is of particular interest since the
conversion pathway yields the PUFA eicosapentaenoic acid (EPA) (20:5n-3) and
docosapentaenoic acid (DHA) (22:6n-3). Figure 1 provides a general pathway for ALA
conversion to longer n-3 PUFA. Studies have not yet shown if the ∆6-Desaturase enzymes that
participate in the conversion pathway are the same enzyme or two distinct ones. Also, both n-3
and n-6 PUFA are metabolized by the same desaturation/elongation pathway, so, therefore, there
exists the potential for competitive competition between n-3 and n-6 PUFA8. In fact, ∆6Desaturase has a greater affinity for ALA although linoleic acid is at greater cellular
concentration than ALA, causing greater conversion of the n-6 PUFA. The effect of increased
consumption of ALA is of interest because of the supposed increase of n-3 PUFA conversion if
ALA intracellular stores were to be increased. Also, the effect of sufficient amounts of
intracellular EPA/DHA, specifically DHA since it has been found to be the primary parameter
affecting visceral fat accumulation6, is of interest since competition for ∆6-Desaturase within the
pathway would lead to feedback inhibition. In fact, the conclusion of a 1994 13C- isotope

incorporation study stated that the conversion of ALA, which entered the desaturase/elongase
pathway, to DHA is 4%9; while a 2002 study of young men found no detectable radioactive
DHA up to 21 days10. Tang et al. found that n-3 and n-6 PUFA suppressed

Figure 1: General pathway for ALA conversion through multiple desaturase and elongase steps (based on
reference 8). The initial reaction is the rate-limiting step. 24:6n-3 is translocation from the ER to the
peroxisome where the acyl chain is shortened. 22:6n-3 (DHA) is translocated back to the ER8.

hepatic expression of rodent ∆6-Desaturase by inhibiting its gene transcription11. Specifically,
∆6-Desaturase contains a response element for the ligand-activated transcription factor
peroxisomal proliferator activated receptor-α (PPARα) in its promoter region, and DHA was
found to bind to PPARα thus promoting the previously mentioned inhibition of ∆6-Desaturase
gene transcription8, 11. The studies lead to the conclusion that feedback inhibition of the
desaturase/elongase pathway by DHA would result in even lower conversion of ALA to EPA
and DHA.
With this knowledge about the feedback inhibition of ALA conversion pathway, a logical
question would be: what happens to the ALA if it does not participate in the conversion to longer
chain n-3 PUFA? We suspect that the excess ALA plays a role in up-regulation of global fatty
acid oxidation in adipocytes and skeletal muscle cells. The excess ALA is most likely
metabolized, but since an ALA-specific oxidation mechanism has not yet been discovered, nor is
one postulated to exist, the increase in ALA oxidation would increase other fatty acid
metabolisms as well.
Materials/Methods:
To determine if surplus ALA regulates global fatty oxidation, experiments were ran using
the C2C12 cell line of mouse adipocytes.
Initial Preparation:
Initial C2C12 mouse adipose tissue line was withdrawn from liquid nitrogen and thawed.
The thawed C2C12 cells were then introduced into a 75cm2 canted neck flask (T75) from Fisher
Scientific™ . The thawed cells were fed with phenol red Dulbecco’s Modified Eagle Medium
(DMEM) high glucose1X (GIBCO®). Penicillin-streptomycin (pen-strep), an antibiotic, and
Fetal Bovine Serum (FBS), a serum-supplement with low level of antibodies and high level of
growth factors, were added at 1% and 10% solution composition, respectively, in order to
diminish risk of contamination and encourage cell growth. The cells were always kept in a 37oC
incubator when not examined or re-fed. The DMEM/10%FBS/1%pen-strep (growth medium)
was changed everyday until the cells became 80-90% confluent. When cells were 80-90%
confluent, they were washed with Hank’s Balanced Salt Solution (HBSS) 3 times, then washed
with trypsin-EDTA 1X (Mediatech™), spun down in 50mL falcon tube to remove supernatant,
and then the pellet of cells were re-suspended in 210mL of the growth medium. Then, the
dilution was split amongst 8x24 well-plates, with 1mL of solution into each well for a total of
192 wells. The growth medium was changed everyday. When the cells in the well-plates became
80-90% confluent, a new DMEM/2%Horse Serum/1%pen-strep (differentiation medium) was
mixed to promote cell differentiation. After 3 days of differentiation medium supplementation, a
new medium serum-free mixture was created containing DMEM/0.2%Horse Serum/1%penstrep. The cells were allowed to incubate for 24 hours in the serum-free mixture before they were
ready for the fatty acids treatments.
Treatments:
Fifteen different treatments were used. The main fatty acids used were arachidonic acid
(ARA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DHA) and α-linlenic acid (ALA).
There were 3 main groups, each with the same 5 ALA concentrations, yielding a total of 15
treatments. The 3 main treatment groups were: the control (solvent), 25µM ARA, and 25µM 3:2
EPA:DHA. Each group had the same 5 ALA concentrations mixed into the solution: 0, 10, 25,

50, and 100µM ALA. The solvent for the treatments was DMEM + Bovine Serum Albumin,
which acts as a transport protein for the fatty acids into the cells.
30X ALA, ARA, and EPA:DHA concentrations were made up from the ethanol dissolved
pure fatty acids. These 30X concentrations were then diluted into the final concentrations by the
solvent. The solvent composed of 495mg of BSA for every 15mL of DMEM needed. To have
sufficient fatty acid treatments, 15mL of each of the 15 treatments were made up and 1mL of the
appropriate treatment was added to the 12 corresponding wells. The treatments were incubated at
37oC/5%CO2 for 12-16 hours.
Fatty Acid Oxidation Protocol:
Reaction Mixture: There The 12 wells per treatment were split into 6 positive,
tritium(5µCi)-labeled protein wells and 6 negative, formalin(10% Phosphate Buffered Solution)labeled wells. The 6 negative wells were labeled with formalin in order to kill the cells and
ensure there would be no activity except background counts recorded. This provides high count
contrast in relation to the tritium-labeled wells and ensures the recorded radioactive was not just
background radioactivity. The reaction mixture added to each well composed of 20mL HBSS, 10
mg BSA, 200µl unlabeled palmitate, and 531µl tritium for the positive controls. For the negative
controls, 531µl of formalin was added, replacing the tritium.
Addition/Incubation: Once the reaction mixture was made, each well received 200 µl of
the appropriate mixture. Any wells that exhibited contamination from the previous ALA
treatments were skipped. After the addition of the appropriate mixtures, the well plates were
incubated at 37oC/5% CO2 for 2 hours.
Protocol Preparation: Chromatography columns with resin solution were prepared the
night before the protocol was run. A total of 180 columns were sorted onto racks, and 2. mL of
resin solution was added to each column. The resin solution composed of 20 g of Dowex ® 1X2,
200-400 mesh, ion-exchange resin (Acros Organics®) for every 55mL of MilliPore® filtered
water. A large beaker was used to contain sufficient resin solution for the 180 columns, and the
solution was constantly stirred via magnet stirring rod until all columns had 2.5mL resin
solution. They were allowed to sit overnight. Also, the night before and/or during the 2 hour
incubation, 2 sets of 180 2mL vials were labeled 1-180 and ordered onto racks for use later in the
protocol. Also, 200µl of trichloroacetic acid (TCA) was added to each tube during the 2 hour
incubation period. The TCA should be 10% wt/vol.
Protocol Procedure: After the 2 hour incubation period, all 8 well-plates were taken out
of the incubator. The mixture from each well was removed and placed into itself appropriately
labeled 2mL vial. When the entire well is finished, 100µl of Phosphate Buffered Saline (PBS)
was added to each well. After 1 minute, the PBS was removed and added to its appropriately
labeled vial. After the vials sat for 2 minutes, they were centrifuged at 8,500g for 5 minutes. At
this time, the twist-off caps at the bottom of the chromatography columns were broken, allowing
the water to sift through the now-settled resin. After the 5 minute centrifuge wait, the supernatant
was removed immediately and placed into the 2nd set of appropriately labeled 2mL vials. A 70µl
addition of 6N NaOH proceeded in order to counteract the TCA. The supernatant/NaOH mixture
was then transferred to its appropriately labeled chromatography column. Each column then
received 1mL of MilliPore® filtered water to facilitate the wash of the supernatant/NaOH
mixture through the resin. The filtrate was collected in an empty scintillation vial and left
overnight. The well-plates now only contained the cell layer, so 500µl of MilliPore® filtered
water was added to each well. The well-plate was then taped shut and put into a -80oC freezer

until ready for the protein correction protocol. The next day, 10mL of Bio-Safe II™ scintillation
fluid was added to each scintillation vial. The vials were then put into a liquid scintillation
counter which recorded the counts per minute (CPMs) at a 1 minute rate. The vials were then
taken out and kept behind a radioactive-material protective hood.
Protein Correction:
Once the CPMs for each well were recorded, a protein correction was run either using the
Commassie Protein Assay Kit (Thermo Scientific ®) or the BCA protein assay reagent kit
(Thermo Scientfic ®). A spectrophotometer assisted by a spectral count program was used to
interpret the data into numerical form. Given this information, the corrected CPM/µg of protein
erased the cell population/well discrepancy from well-to-well.
Results:
Data/Interpretation:
The initial experiment data, for the 3:2 25µM EPA:DHA treatments, show a 141%, 41%,
195%, and 97% increase in fat oxidation in response to progressive increases in ALA from 0 to
10, 25, 50, and 100µM ALA concentrations, respectively (Figure 2). Also, the 25µM ARA
treatments show an initial decrease of 4.1%, but then a rebound of 31%, 266% before another
loss in oxidation of 32% in response to progressive increases in ALA from 0 to 10, 25, 50, and
100µM ALA, respectively (Figure 3). The initial data for both EPA:DHA and ARA treatments
show increases in fat oxidation for palmitate (16:0). There was an observed 33% and 82%
decrease in fat oxidation from 50 to 100µM ALA concentrations within the EPA:DHA and ARA
treatments, respectively, suggesting a possible threshold for increasing oxidation at 50µM ALA
for both treatments.
For the subsequent experiment, the EPA:DHA treatments showed decreases of 47%,
30%, 36%, and 34% in fat oxidation from 0 to 10, 25, 50, and 100µM ALA concentrations,
respectively. The ARA treatments showed initial increases of 54%, 27%, and then decreases of
1.6% and 29%, respectively.
The initial experiment did suggest a ALA-stimulated increase in palmitate oxidation, but
only one subsequent experiment was ran due to time constraints and its data did not replicate the
initial experiment’s. Due to lack of consistent data, this study’s interpretation of whether ALA
does up-regulate fatty acid oxidation will be left inconclusive until more repeat experiments are
run.
Sources of Error:
Similar to any scientific experiment, there are possible sources of error that should be
enumerated in order to maintain scientific integrity.
Aside from any inherent human error, certain initial and subsequent ARA and EPA:DHA
treatments did not have the full 6 positive and 6 negative controls as listed in the Fatty Acid
Oxidation Protocol above. In the ARA initial treatments, 0 and 25µM ALA concentrations had 4
and 5 positive controls, respectively. In the EPA:DHA initial treatments, 25µM ALA
concentration had 5 positive controls. In the subsequent ARA experiment, 25µM
ALA concentration had 5 positive controls. In the subsequent EPA:DHA experiment, 0µM ALA
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Figure 2: Initial experiment changes in palmitate oxidation at various concentrations of ALA within the
EPA:DHA treatments. The data suggests ALA-stimulated increase in fat oxidation and a possible threshold
for oxidation around 50uM ALA. Error bars represent the standard error of the mean.
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Figure 3: Initial experiment changes in palmitate oxidation at various concentrations of ALA within the ARA
treatments. The data also suggests ALA-stimulated increase in fat oxidation and a possible threshold for
oxidation around 50uM ALA. Error bars represent the standard error of the mean.

concentration had 5 positive controls. One or two fewer positive, tritium-labeled controls
increases the susceptibility of the mean to outliers in the data, therefore, leading to sample data
that are not representative of the proposed cell population. A solution would be to run more
repeat experiments in the future to obtain more sample data, therefore, making the complete
sample data more representative of the proposed cell population.

Another possible source of error stems from the time dedicated to finishing the fatty acid
oxidation protocol. With only one researcher working through the protocol, each plate took about
45 minutes to complete meaning that the 8th plate could have sat at room temperature for 6 hours
before beginning the protocol after the 2 hour incubation period. This extra time, even though at
room temperature, could have affected the recorded CPM of the latter treatment plates. A
solution would be to have more than one researcher completing the protocol once started and/or
investigating the effects of refrigerating the treatment plates until they are needed after the 2 hour
incubation period.
Future/Proposed Experiments:
Multiple repeat experiments will have to be run to obtain consistent data before any of
the following hypotheses will be tested.
Mechanisms of Action:
If the repeat experiment suggest ALA dose-dependent up-regulation of fatty acid
oxidation response, the next step would be to understand exactly how these increases in fatty
acid oxidation are caused.
Carnitine palmitoyltransferase I (CPT1) is one of the cycle carnitine enzymes that
transport long chain fatty acids from the cytoplasm into the mitochondria12 for incorporation into
the β-oxidation pathway. Hypothesized mechanisms to investigate are the up-regulation of
CPT1, and more specifically CPT1B, the muscle-type isoform of CPT112, activity.
Also, there is significant interest in the role of PPARα and PPARδ, PPAR isoforms, in
the regulation of fatty acid oxidation. Studies have found that the PPARs modulated enzymes
involved in lipid metabolism, especially in metabolically active tissues such as sketetal and
adipose, thus suggesting that they may play a key role in energy metabolism and affect weight
gain8, 13.
Future studies will be run that will investigate these proposed mechanisms of action of
fatty acid oxidation regulation. Also, repeat fatty acid oxidation protocol experiments will be ran
in order to obtain more sample data, which will better illustrate the observed trends of the 15
treatments.
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